Monopar Therapeutics Q1 2024 GAAP EPS $(0.10) Beats $(0.14) Estimate
Portfolio Pulse from Benzinga Newsdesk
Monopar Therapeutics (NASDAQ:MNPR) reported Q1 2024 GAAP EPS losses of $(0.10) per share, surpassing the analyst consensus estimate of $(0.14) by 28.57%. This represents a 47.37% improvement over the previous year's losses of $(0.19) per share.
May 09, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Monopar Therapeutics reported a smaller than expected Q1 2024 loss of $(0.10) per share, beating estimates and showing significant year-over-year improvement.
Beating EPS estimates typically has a positive impact on investor sentiment and can lead to a short-term increase in stock price. The significant improvement over the previous year's losses further strengthens the positive outlook for MNPR.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100